SCHEMBL4536997

SCHEMBL4536997

CNC(=CC(=O)O)c1ccccc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 3/20 0.45
MAPK1 P28482 2/20 0.45
ALDH1A1 P00352 2/20 0.45
SRC P12931 1/20 0.44
TSHR P16473 3/20 0.43
MEN1 O00255 4/20 0.42
KMT2A Q03164 4/20 0.42
NFE2L2 Q16236 1/20 0.42
CES1 P23141 4/20 0.41
MAPT P10636 3/20 0.41
ALOX15 P16050 2/20 0.41
CYP3A4 P08684 2/20 0.41
KDM4E B2RXH2 1/20 0.41
HPGD P15428 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
CES2 O00748 3/20 0.41
DAO P14920 1/20 0.41
NAPRT Q6XQN6 1/20 0.41
CA12 O43570 2/20 0.41
CA1 P00915 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4536988 1.00 TDP1 (0.45) TDP1MAPK1ALDH1A1SRCTSHR
SCHEMBL4536993 1.00 TDP1 (0.45) TDP1MAPK1ALDH1A1SRCTSHR
SCHEMBL21659115 0.86 MTNR1A (0.44) TDP1MAPK1ALDH1A1SRCTSHR
SCHEMBL1928740 0.82 MAPT (0.44) ALDH1A1MEN1KMT2ACES1MAPT
SCHEMBL388144 0.82 MTNR1A (0.44) TDP1MAPK1ALDH1A1SRCTSHR
SCHEMBL5072835 0.82 MTNR1A (0.44) TDP1MAPK1ALDH1A1SRCTSHR
SCHEMBL6648182 0.82 MTNR1A (0.44) TDP1MAPK1ALDH1A1SRCTSHR
SCHEMBL387761 0.80 MTNR1A (0.43) TDP1MAPK1ALDH1A1SRCTSHR
SCHEMBL23193036 0.79 NFE2L2 (0.38) TDP1MAPK1ALDH1A1SRCTSHR
SCHEMBL1942392 0.79 ALDH1A1 (0.52) ALDH1A1MEN1KMT2AALOX15KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1879607-B1 HCV NS3 PROTEASE INHIBITORS MERCK SHARP & DOHME (US) 2014-11-12 EP disclosed
US-20090075869-A1 HCV NS3 protease inhibitors MERCK SHARP & DOHME LLC 2009-03-19 US disclosed
EP-1879607-A2 HCV NS3 PROTEASE INHIBITORS Merck & Co., Inc. (US) 2008-01-23 EP disclosed
WO-2006119061-A2 HCV NS3 PROTEASE INHIBITORS MERCK & CO., INC. (US) 2006-11-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090075869-A1 HCV NS3 protease inhibitors HAVCR2, GTF3C3, CTSC TDP1 3107/4885MAPK1 2367/4885ALDH1A1 1199/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.